Covid-19 Related Delays in the Ongoing Phase IIb-study are Expected to be Managed With Existing Funding
STOCKHOLM, April 2, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, on April 2 2020, that the company is now seeing signs of delays in the ongoing clinical phase IIb study with the drug candidate RV001 in prostate cancer, due to the Covid-19 pandemic. However, the company believes that the delays that can be foreseen now are covered by existing financing.
RhoVac's ongoing clinical phase IIb clinical trial, called BRaVac, is a randomized, placebo-controlled and double-blinded study, with the primary study aim to evaluate whether treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative treatment. The clinical phase IIb study is an international, multicenter study, which will recruit over 175 patients in six European countries - Denmark, Finland, Sweden, Belgium, Germany and the UK, as well as in the USA. Patients who have already begun treatment with RhoVac's drug candidate RV001 are expected to continue as planned, while work on recruiting more patients is likely to be delayed due to the Covid-19 pandemic. RhoVac continues with the remaining regulatory and administrative preparations in the countries that have not yet started, and the company is already taking appropriate measures to minimize the delay that may be caused by the current health care reprioritization measures. For example, the company is currently preparing to open about ten more clinical trial sites than originally planned. Even so, delays are foreseen, but RhoVac estimates that existing financing will cover the expected delays.
CEO Anders Månsson comments: "No company goes unaffected by the Covid-19 pandemic and we understand and respect the priorities that healthcare faces. RhoVac stands stronger than most companies because we are not dependent on revenue that is now missing, and because the company's financing was strengthened considerably last summer. Overall, we have funding that is expected to cover the company's needs through to the second half of 2022, which we believe will be sufficient to get through the Covid-19 crisis, conduct the study, and reach a possible exit point."
For further information, please contact:
Anders Månsson - CEO
RhoVac AB
Phone number: +46-73-751-72-78
E-mail: [email protected]
This information is such that RhoVac AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 2nd April 2020.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE RhoVac
Share this article